Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psychiatric Diseases and Institute of Neuroscience, The Second Affiliated Hospital, Soochow University, Suzhou, 215123, China.
Center for Translational Medicine, Affiliated Zhangjiagang Hospital of Soochow University, Zhangjiagang, 215600, China.
Neurosci Bull. 2017 Dec;33(6):711-721. doi: 10.1007/s12264-017-0195-1. Epub 2017 Dec 1.
Voltage-dependent anion channel 1 (VDAC1) is thought to contribute to the progression of tumor development. However, whether VDAC1 contributes to bone cancer pain remains unknown. In this study, we found that the expression of VDAC1 was upregulated in the L2-5 segments of the spinal dorsal horn at 2 and 3 weeks after injection of tumor cells into the tibial cavity. Intrathecal injection of a VDAC1 inhibitor significantly reversed the pain hypersensitivity and reduced the over-expression of Toll-like receptor 4 (TLR4). Intrathecal injection of minocycline, an inhibitor of microglia, also attenuated the pain hypersensitivity of rat models of bone cancer pain. These results suggest that VDAC1 plays a significant role in the development of complicated cancer pain, possibly by regulating the expression of TLR4.
电压门控阴离子通道 1（VDAC1）被认为有助于肿瘤发展。然而，VDAC1 是否有助于骨癌疼痛尚不清楚。在这项研究中，我们发现肿瘤细胞注入胫骨腔后 2 至 3 周，VDAC1 的表达在 L2-5 脊髓背角节段上调。鞘内注射 VDAC1 抑制剂可显著逆转痛觉过敏，并降低 Toll 样受体 4（TLR4）的过度表达。鞘内注射小胶质细胞抑制剂米诺环素也可减轻骨癌痛大鼠模型的痛觉过敏。这些结果表明，VDAC1 在复杂癌痛的发展中起重要作用，可能通过调节 TLR4 的表达。
